Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram

Schizophrenia Bulletin

Volumn 32, Issue 4, 2006, Pages 644-654

  Petrakis, Ismene L ^a   Nich, Charla ^a   Ralevski, Elizabeth ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcoholism; Comorbidity; Disulfiram; Naltrexone; Pharmacotherapy; Psychosis

Indexed keywords

ACAMPROSATE; ACETALDEHYDE; ALCOHOL; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; DISULFIRAM; LITHIUM; MU OPIATE RECEPTOR ANTAGONIST; NALTREXONE; NEUROLEPTIC AGENT; PLACEBO;

ABDOMINAL PAIN; ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; COMORBIDITY; DELIRIUM; DEPRESSION; DISEASE EXACERBATION; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; HUMAN; MANIA; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOSOCIAL CARE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SWEATING; TREMOR;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; BIPOLAR DISORDER; COMBINED MODALITY THERAPY; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); DISULFIRAM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTIVATION; NALOXONE; NARCOTIC ANTAGONISTS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME; VETERANS;

EID: 33748798484     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbl010     Document Type: Article

References (70)

1. Regier DA, Farmer ME, Rae DS. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) study. JAMA. 1990; 264:2511-2518.
2. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999; 35(suppl):S93-S100.
3. Gerding LB, Labbate LA, Measom MO, Santos AB, Arana GW. Alcohol dependence and hospitalization in schizophrenia. Schizophr Res. 1999;38:71-75.
4. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv. 1996;47:853-858.
5. Miles H, Johnson S, Amponsah-Afuwape S, Finch E, Leese M, Thornicroft G. Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatr Serv. 2003;54:554-561.
6. Wallace C, Mullen PE, Burgess P. Criminal offending in schizophrenia over a 25-year period marked by deinstitutionalization and increasing prevalence of comorbid substance use disorders. Am J Psychiatry. 2004;161:716-727.
7. Petrakis IL, O'Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology. 2004;172:291-297.
8. Ziedonis D, Richardson T, Lee E, Petrakis IL, Kosten T. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull. 1992;28:309-314.
9. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62: 37-45.
10. Noordsy DL, Schwab B, Fox L, Drake RE. The role of self-help programs in the rehabilitation of persons with severe mental illness and substance use disorders. Community Ment Health J. 1996;32:71-81; discussion 83-86.
11. Garbutt J, West S, Carey T, Lohr K, Crews F. Pharmacological treatment of alcohol dependence, a review of the evidence. JAMA. 1999;281:1318-1325.
12. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA. 1986;256:1449-1455.
13. Bigelow G, Stricker D, Liebson E, Griffiths R. Maintaining disulfiram ingestion among outpatient alcoholic: a security-deposit contingency contracting procedure. Behav Res Ther. 1976;14:378-381.
14. Keane TM, Foy DW, Nunn B, Rychtarik RG. Spouse contracting to increase antabuse compliance in alcoholic veterans. J Clin Psychol. 1984;40:340-344.
15. O'Farrell TJ, Bayog RD. Antabuse contracts for married alcoholics and their spouses: a method to maintain antabuse ingestion and decrease conflict about drinking. J Subst Abuse Treat. 1986;3:1-8.
16. Fuller R, Roth H, Long S. Compliance with disulfiram treatment of alcoholism. J Chronic Dis. 1983;36:161-170.
17. Larson EW, Olincy A, Rummans TA, Morse RM. Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review. Alcohol Clin Exp Res. 1992;16: 125-130.
18. Fisher CM. 'Catatonia' due to disulfiram toxicity. Arch Neurol. 1989;46:797-804.
19. Mueser K, Noordsy D, Fox L, Wolfe R. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict. 2003;12:242-252.
20. Froehlich J, O'Malley S, Hyytia P, Davidson D, Farren C. Preclinical and clinical studies on naltrexone: what have they taught each other? Alcohol Clin Exp Res. 2003;27: 533-539.
21. Volpicelli J, Alterman A, Hayashida M, O'Brien C. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
22. O'Malley S, Jaffe A, Chang G, Schottenfeld R, Meyer R, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49:881-887.
23. Anton RF, Moak DH, Waid R, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for treatment of outpatient alcoholics: result a placebo-controlled trial. Am J Psychiatry. 1999;156:1758-1764.
24. Kranzler H, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335-1341.
25. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21:287-292.
26. Kranzler HR, Armeli S, Tennen H, et al. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol. 2003;23:294-304.
27. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial [see comment]. JAMA. 2006;295:2003-2017.
28. Kranzler H, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology. 2000;22:493-503.
29. Gastpar MT, Bonnet U, Boning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol. 2002;22:592-598.
30. Krystal JH, Cramer J, Krol W, Kirk G, Rosenheck R. Naltrexone in the treatment of alcohol dependence. New Engl J Med. 2001;345:1734-1739.
31. Fuller R, Gordis E. Naltrexone treatment for alcohol dependence. New Engl J Med. 2001;345:1770-1771.
32. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial [comment]. Addiction. 2001;96:1565-1573.
33. Maxwell S, Shinderman MS. Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J Addict Dis. 2000;19:61-69.
34. Salloum I, Cornelius J, Thase M, Daley D, Kirisci L, Spotts C. Naltrexone utility in depressed alcoholics. Psychopharmacology. 1998;34:111-115.
35. Petrakis IL, Leslie D, Rosenheck R. Use of naltrexone in the treatment of alcoholism nationally in the department of veterans affairs. Alcohol Clin Exp Res. 2003;27:1780-1784.
36. Batki S, Dimmock J, Leontieva L, et al. Recruitment and characteristics of alcohol dependent patients with schizophrenia. Alcohol Clin Exp Res. 2005;29:78A.
37. Batki S, Dimmock J, Cornell M, Wade M, Carey K, Maisto S. Directly observed naltrexone treatment of alcohol dependence in schizophrenia: preliminary analysis. Alcohol Clin Exp Res. 2002;26:83A.
38. Petrakis IL, Poling J, Levinson C, Nich C, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry. 2005;57:1128-1137.
39. Sbrana A, Dell'Osso L, Benvenuti A, et al. The psychotic spectrum: validity and reliability of the Structured Clinical Interview for the Psychotic Spectrum. Schizophr Res. 2005;75: 375-387.
40. Bellack A, Bennett M, Gearon J, Brown C, Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry. 2006;63:426-432.
41. First MD, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders (Patient Edition) (SCID-P). Biometric Research. New York: New York State Psychiatric Institute; 1996.
42. Skinner HA, Horn JL. Alcohol Dependence Scale (ADS): User's Guide. Toronto, Canada: Addiction Research Foundation; 1984.
43. Sobell LC, Sobell MB. Timeline Follow-Back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J, eds. Measuring Alcohol Consumption. Totowa, NJ: The Humana Press; 1992:41-72.
44. Anton RF, Moak DH, Latham PK. The Obsessive Compulsive Drinking Scale: a new method of assessing outcome in alcoholism treatment studies [published erratum appears in Arch Gen Psychiatry. 1996;53:576]. Arch Gen Psychiatry. 1996;53:225-231.
45. Kay S, Fiszbein A, Opler L. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
46. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974;19:1-15.
47. Hedeker D, Gibbons R, Davis J. Random regression models for multicenter clinical trials data. Psychopharmacol Bull. 1991;27:73-77.
48. Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995;19:92-99.
49. Koob GF. Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci. 2000;909:170-185.
50. Chick J. UK multicenter study of naltrexone as adjunctive therapy in the treatment of alcoholism: efficacy results. Abstr X World Congr Psychiatry. 1996;1:230.
51. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence. Role of subject compliance [see comment]. Arch Gen Psychiatry. 1997;54:737-742.
52. Kranzler HR, Wesson DR, Billot L. Drug G. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28:1051-1059.
53. Sinha R, O'Malley SS. Craving for alcohol: findings from the clinic and the laboratory. Alcohol Alcohol. 1999;34:223-230.
54. Herbeck DM, Fitek DJ, Svikis DS, Montoya ID, Marcus SC, West JC. Treatment compliance in patients with comorbid psychiatric and substance use disorders. Am J Addict. 2005;14:195-207.
55. Food and Drug Administration (FDA). Center for Drug Evaluation and Research Approval Package for: Application Number 21-431; 2004. Available at: http://www.fda.gov/cder/foi/ nda/2004/21-431_Campral.htm. Accessed August 1, 2006.
56. Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology. 2002;27:596-606.
57. Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction. 1995;90:1179-1188.
58. Mason B. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001;62(20): 42-48.
59. Buckley PF. Substance abuse in schizophrenia: a review. J Clin Psychiatry. 1998;59(suppl 3):26-30.
60. Albanese MJ, Khantzian EJ, Murphy SL, Green AI. Decreased substance use in chronically psychotic patients treated with clozapine [letter]. Am J Psychiatry. 1994;151:780-781.
61. Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: a case report and a hypothesis. J Nerv Ment Dis. 1994;182:591-592.
62. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine. Am J Psychiatry. 1995;152:959.
63. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26:441-449.
64. Volavka J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psychiatry. 1999;60(suppl 12):43-46.
65. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003;60:81-85.
66. Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol. 2000;20:94-98.
67. Mueller TI, Stout RL, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21:86-92.
68. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152:391-397.
69. Johnson B, Ait-Daoud N, Bowden C, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677-1685.
70. Nasr S. Oxcarbazepine for mood disorders. Am J Psychiatry. 2002;159:1793.